Table 2

Psoriasis exacerbation and other IrAEs

Exacerbation informationNo of patients (%, N=76)
Experienced psoriasis flare43 (57)
 Cutaneous involvement39 (51)
 Extracutaneous manifestations7 (9)
 Arthritis6 (8)
 Iritis1 (1)
Time (days) from ICI initiation to flare, median (range)43.5 (1–725)
Worst grade of psoriasis flare
 115 (20)
 221 (28)
 36 (8)
 41 (1)
Treatment for psoriasis flare
 Acitretin*3 (4)
 Methotrexate†1 (1)
 Prednisone‡9 (12)
 Small molecule inhibitors§3 (4)
 Topicals only23 (30)
Total patients with other irAE45 (59)
 Colitis (including diarrhea)16 (21)
 Skin (excluding psoriasis)13 (17)
 Endocrine11 (14)
 Liver11 (14)
 Joint6 (8)
 Lung3 (4)
 Mucositis/oral cavity2 (3)
 Other3 (34)
Grade 3 or 4 other irAE17 (22)
 Colitis (including diarrhea)7 (9)
 Skin (excluding psoriasis)2 (3)
 Endocrine0
 Liver5 (7)
 Joint1 (1)
 Lung2 (3)
 Mucositis/oral cavity0
 Other0
Grade 3 or 4 other irAE per immunotherapy class
 Anti-PD-1/PD-L18 (16)
 Anti-CTLA-43 (37.5)
 Combination6 (35)
Reason for immunotherapy discontinuation
 Treatment completion/response/patient decision17 (22)
 Psoriasis flare5 (7)
 Other irAE22 (29)
 Disease progression22 (29)
 Other (including ongoing treatment)10 (13)
  • *Two patients treated with topicals.

  • †One patient treated with prednisone/topicals.

  • ‡Three patients treated with topicals, one with acitretin, one with small molecule inhibitor/topicals.

  • §One patient treated with acitretin/topicals, one with topicals.

  • ICI, immune checkpoint inhibitor; irAEs, immune-related adverse events.